This trial is testing whether ATG can be replaced with tocilizumab in the haplo-cord transplant conditioning regimen to improve immune reconstitution and reduce relapse while preserving low rates of graft failure and graft versus host disease.
- Blood Cancers
- Bone Marrow Transplant
1 Primary · 7 Secondary · Reporting Duration: 5 years post-transplant
Side Effects for
4 Treatment Groups
ATG Group III
1 of 4
ATG Group IV
1 of 4
ATG Group I
1 of 4
ATG Group II
1 of 4
70 Total Participants · 4 Treatment Groups
Primary Treatment: Tocilizumab · No Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is registration still open for this trial?
"The clinicaltrials.gov website verifies that this medical investigation, which was posted on October 7th 2020, is currently hunting for participants. It has been modified recently, with the last change made on September 20th 2022." - Anonymous Online Contributor
What is the limit of subjects enrolled in this experiment?
"Affirmative. Clinicaltrials.gov reveals that this clinical trial is actively recruiting, with the initial posting on October 7th 2020 and its most recent update occurring on September 20th 2022. 70 participants are needed from a single site for this study to be successful." - Anonymous Online Contributor
Has the FDA given Tocilizumab its stamp of approval?
"Given its Phase 2 status, meaning that there is safety data but not efficacy information, our group at Power assigned Tocilizumab a score of 2 on the 1-3 scale." - Anonymous Online Contributor
What medical conditions is Tocilizumab commonly employed to treat?
"Tocilizumab is efficacious for the management of immunosuppressive treatment, kidney maladies, and amyloidosis." - Anonymous Online Contributor